Financiere des Professionnels Fonds d investissement inc. Acquires New Holdings in Eli Lilly and Company $LLY

Financiere des Professionnels Fonds d investissement inc. purchased a new position in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,258 shares of the company’s stock, valued at approximately $960,000.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of Eli Lilly and Company by 499.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 18,088 shares of the company’s stock valued at $14,939,000 after acquiring an additional 15,071 shares in the last quarter. Petrus Trust Company LTA purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at approximately $425,000. Finally, Raab & Moskowitz Asset Management LLC increased its stake in Eli Lilly and Company by 3.1% during the 1st quarter. Raab & Moskowitz Asset Management LLC now owns 1,996 shares of the company’s stock valued at $1,649,000 after purchasing an additional 60 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on LLY shares. Leerink Partnrs raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. UBS Group restated a “neutral” rating on shares of Eli Lilly and Company in a research note on Thursday, December 18th. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Monday, December 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Finally, HSBC reissued a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Five analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $1,155.36.

Eli Lilly and Company Trading Up 0.5%

Shares of LLY stock opened at $1,079.83 on Monday. The stock’s fifty day moving average is $1,013.16 and its two-hundred day moving average is $851.29. The firm has a market capitalization of $1.02 trillion, a P/E ratio of 52.83, a PEG ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company posted $1.18 EPS. The business’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 33.86%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.